You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 1, 2024

CLINICAL TRIALS PROFILE FOR APALUTAMIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Apalutamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01171898 ↗ Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) Active, not recruiting Aragon Pharmaceuticals, Inc. Phase 1/Phase 2 2010-07-26 The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.
NCT01946204 ↗ A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Active, not recruiting Aragon Pharmaceuticals, Inc. Phase 3 2013-10-14 The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
NCT02106507 ↗ ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate Completed Aragon Pharmaceuticals, Inc. Phase 1 2014-04-01 The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
NCT02106507 ↗ ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate Completed Memorial Sloan Kettering Cancer Center Phase 1 2014-04-01 The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Apalutamide

Condition Name

Condition Name for Apalutamide
Intervention Trials
Prostate Cancer 39
Prostate Adenocarcinoma 13
Prostatic Neoplasms 13
Stage IVA Prostate Cancer AJCC v8 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Apalutamide
Intervention Trials
Prostatic Neoplasms 100
Adenocarcinoma 19
Carcinoma 9
Hypersensitivity 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Apalutamide

Trials by Country

Trials by Country for Apalutamide
Location Trials
United States 502
Canada 51
Brazil 22
Japan 19
Spain 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Apalutamide
Location Trials
California 35
New York 30
Texas 27
Pennsylvania 21
Ohio 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Apalutamide

Clinical Trial Phase

Clinical Trial Phase for Apalutamide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 17
Phase 2/Phase 3 2
[disabled in preview] 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Apalutamide
Clinical Trial Phase Trials
Recruiting 42
Active, not recruiting 24
Not yet recruiting 21
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Apalutamide

Sponsor Name

Sponsor Name for Apalutamide
Sponsor Trials
National Cancer Institute (NCI) 18
Janssen Research & Development, LLC 12
Janssen Scientific Affairs, LLC 12
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Apalutamide
Sponsor Trials
Industry 86
Other 86
NIH 19
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.